NCT02774278 - A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter

Enrollment

264

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG

Erlotinib

Erlotinib will be administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death.

Trial Locations (29)

8

Dublin

105

Taipei

106

Taipei

1756

Sofia

11619

Tallinn

22927

Großhansdorf

28041

Madrid

34295

Montpellier

50937

Cologne

51014

Tartu

75970

Paris

105229

Moscow

107005

Moscow

115478

Moscow

169610

Singapore

197089

Saint Petersburg

197758

Saint Petersburg

198255

Saint Petersburg

B-1200

Brussels

Unknown

Hong Kong

06132

Perugia

80-214

Gdansk

94-306

Lodz

20-950

Lublin

60-569

Poznan

08035

Barcelona

08916

Barcelona

00112

Taipei

BS23 4TQ

Weston-super-Mare

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY